A Phase 3 interventional study of Rimegepant 75mg Orally Disintegrating Tablets (ODT) in Acute Migraine, sponsored by Pfizer. Completed at 26 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-20.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies testing rimegepant in Migraine Disorders — 13 open to participants now, 15 under way, 6 of them phase 3. rimegepant · Migraine Disorders.
Among the 32 studies testing rimegepant in Migraine Disorders, this one is the 24th largest by enrollment, is one of 8 that started in 2022, is one of 14 in phase 3, and was the 14th registered.
1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.
Browse Migraine Disorders studies →13 of the 32 studies testing rimegepant in Migraine Disorders are open now, in 12 countries. Recruiting first, the newest first:
University of South Florida · Sites in United States
Ages 18+ · Healthy volunteers
Pfizer · Sites in United States, Israel
Ages 18+
Pfizer · Sites in India
Ages 18+
Pfizer · Sites in United States, Israel
Ages 18+
Medstar Health Research Institute · Sites in United States
Ages 18+
By country, each count listing its studies:
rimegepant: first FDA approval 2020 (NURTEC ODT), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 16 · Phase 4 9
First in 2011; this study’s year is marked. 8 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 241 is above the median of 80 across 1,269 interventional studies indexed under Migraine Disorders.
Median enrollment 618 across the 32 interventional studies. Of the 17 that completed or were terminated, 15 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 32 have an industry lead sponsor. The 8 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
47 studies in Migraine Disorders by Pfizer: 10 open now, 14 under way, 6 of them phase 3. Of 30 finished, 24 (80%) have results posted.
Among the 47 studies in Migraine Disorders by Pfizer, this one is the 27th largest by enrollment of the 37 interventional ones that give a count, is one of 8 that started in 2022, is one of 18 in phase 3, and was the 25th registered.
Pfizer’s Migraine Disorders studies by the year they started, since 2007.
3 of the studies testing rimegepant in Migraine Disorders that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06641466Phase 3PfizerA Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine | 2026-11-29 |
| NCT07918053Chinese PLA General HospitalA Prospective Study of Rimegepant for Short-term Preventive Treatment of Night-shift-related Migraine in Healthcare Professionals | 2027-06 |
| NCT07667621University of South FloridaA Prospective, Open-Label Study Evaluating the Effectiveness of Gepants for Acute Treatment of Migraine in the Emergency Department | 2027-07 |
Add all 3 to your calendar (.ics) → With an account.
Among the 32 studies testing rimegepant in Migraine Disorders, from their registry updates:
Among Pfizer’s 47 in Migraine Disorders:
This tab as a report to print or save as PDF → With an account.
This trial is to evaluate the long-term safety and tolerability of Rimegepant 75mg ODT in Chinese subjects with migraine
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
At least a one-year history of migraines (with or without aura), consistent with a diagnosis according to the International Classification of Headache Disorders, 3rd edition beta version, including the following:
Age and Reproductive Status:
Exclusion Criteria:
Target Disease Exclusion:
* Subjects has a history of basilar migraine with brain stem aura or hemiplegic migraine
Medical History and Comorbidities:
Subjects who are positive for amphetamines on the urine drug screen may have their urine samples evaluated for further analysis at the investigator's discretion to rule out a false positive result
Allergy and Adverse Reactions:
*. History of drug or other allergy that, in the opinion of the investigator, would make the subject unsuitable for participation in the study
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One rimegepant (BHV3000) 75mg orally disintegrating tablet (up to 1 tablet per day)
Drug: Rimegepant 75mg Orally Disintegrating Tablets (ODT)
One rimegepant (BHV3000) 75mg orally disintegrating tablet (up to 1 tablet per day) at the time of their migraine attack
Treatment Safety Period: Number of Participants With Treatment Emergent Adverse Events (TEAEs)
An adverse event was any untoward medical occurrence in a clinical trial participant administered an investigational product that may present with symptoms/signs, disease, or laboratory abnormalities and which did not necessarily have a causal relationship with the investigational product. TEAEs were events that started after the first dose of trial drug and did not occur or worsen relative to the first dose.
Time frame: From Day 1 of study treatment up to Week 52 of the treatment safety period
Follow-up Safety Period: Number of Participants With TEAEs
An adverse event was any untoward medical occurrence in a clinical trial participant administered an investigational product that may present with symptoms/signs, disease, or laboratory abnormalities and which did not necessarily have a causal relationship with the investigational product. TEAEs were events that started after the first dose of trial drug and did not occur or worsen relative to the first dose.
Time frame: From Week 52 to Week 54 of the follow-up safety period
Treatment Safety Period: Number of Participants With Serious Adverse Events (SAEs)
An adverse event was any untoward medical occurrence in a clinical trial participant administered an investigational product that may present with symptoms/signs, disease, or laboratory abnormalities and which did not necessarily have a causal relationship with the investigational product. SAE referred to any untoward medical occurrence that met any of the following criteria at any dose for a participant that received the investigational product: death, life-threatening, permanent or severe disability or incapacity, hospitalization or prolongation of hospitalization required or congenital anomaly or birth defect.
Time frame: From Day 1 of study treatment up to Week 52 of the treatment safety period
Follow-up Safety Period: Number of Participants With SAEs
An adverse event was any untoward medical occurrence in a clinical trial participant administered an investigational product that may present with symptoms/signs, disease, or laboratory abnormalities and which did not necessarily have a causal relationship with the investigational product. SAE referred to any untoward medical occurrence that met any of the following criteria at any dose for a participant that received the investigational product: death, life-threatening, permanent or severe disability or incapacity, hospitalization or prolongation of hospitalization required or congenital anomaly or birth defect.
Time frame: From Week 52 to Week 54 of the follow-up safety period
Treatment Safety Period: Number of Participants With AEs Leading to Study Drug Discontinuation
An AE was any untoward medical occurrence in a clinical trial participant administered an investigational product that may present with symptoms/signs, disease, or laboratory abnormalities and which did not necessarily had a causal relationship with the investigational product. AEs that led to study drug discontinuation were reported in this outcome measure.
Time frame: From Day 1 of study treatment up to Week 52 of the treatment safety period
Follow-up Safety Period: Number of Participants With AEs Leading to Study Drug Discontinuation
An AE was any untoward medical occurrence in a clinical trial participant administered an investigational product that may present with symptoms/signs, disease, or laboratory abnormalities and which did not necessarily had a causal relationship with the investigational product. AEs that led to study drug discontinuation were reported in this outcome measure.
Time frame: From Week 52 to Week 54 of the follow-up safety period
Treatment Safety Period: Number of Participants With Electrocardiogram (ECG) Abnormalities
ECG abnormalities criteria included: QT Interval Corrected Using Fridericia's Formula (QTcF) millisecond (msec): less than or equal to (\<=)450, 450 - \<=480, 480- \<=500, greater than (\>)500.
Time frame: From Day 1 of study treatment up to Week 52 of the treatment safety period
Follow-up Safety Period: Number of Participants With ECG Abnormalities
ECG abnormalities criteria included: QTcF msec: \<=450, 450 - \<=480, 480- \<=500, \>500.
Time frame: From Week 52 to Week 54 of the follow-up safety period
Treatment Safety Period: Number of Participants With Vital Signs Abnormalities
Vital signs abnormalities included blood pressure (BP) millimeters of mercury (mmHg): systolic BP \<90 and \>140; diastolic BP \<50 and \>90 and pulse rate (beats per minute) :\<40 and \>120.
Time frame: From Day 1 of study treatment up to Week 52 of the treatment safety period
Follow-up Safety Period: Number of Participants With Vital Signs Abnormalities.
Vital signs abnormalities included BP mmHg: systolic BP \<90 and \>140; diastolic BP \<50 and \>90 and pulse rate (beats per minute) :\<40 and \>120.
Time frame: From Week 52 to Week 54 of the follow-up safety period
Treatment Safety Period: Number of Participants With Hematology Test Abnormalities
Hematology parameters included: hemoglobin increased, anemia, leukocytosis, white blood cell decreased, platelet count decreased, neutrophil count decreased, lymphocyte count increased, lymphocyte count decreased. As per National Cancer Institute of Common Terminology Criteria for Adverse Events (NCI CTCAE) version(v)5.0-Grade(G) 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated, Grade 2: moderate; minimal, local or non-invasive intervention indicated; limiting age appropriate instrumental activities of daily living (ADL), Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL. Grade 4: life-threatening consequences; urgent intervention indicated. Grade 5: death related to AE. Grade 3 and 4 abnormalities were reported in this outcome measure.
Time frame: From Day 1 of study treatment up to Week 52 of the treatment safety period
Follow-up Safety Period: Number of Participants With Hematology Test Abnormalities
Hematology parameters included: hemoglobin increased, anemia, leukocytosis, white blood cell decreased, platelet count decreased, neutrophil count decreased, lymphocyte count increased, lymphocyte count decreased. As per NCI CTCAE v5.0-Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated, Grade 2: moderate; minimal, local or non-invasive intervention indicated; limiting age-appropriate instrumental ADL, Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL. Grade 4: life-threatening consequences; urgent intervention indicated. Grade 5: death related to AE. Grade 3 and 4 abnormalities were reported in this outcome measure.
Time frame: From Week 52 to Week 54 of the follow-up safety period
Treatment Safety Period: Number of Participants With Chemistry Test Abnormalities
Chemistry Test Abnormalities included: hypernatremia, hyponatremia, hyperkalemia, hypokalemia, hypoglycemia, creatinine increased, blood lactate dehydrogenase increased, hypoalbuminemia, creatine phosphokinase (CPK) increased, aspartate aminotransferase increased, alanine aminotransferase increased, blood bilirubin increased, alkaline phosphatase increased, chronic kidney disease, cholesterol high, hypertriglyceridemia. As per NCI CTCAE v5.0-G1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated, G2: moderate; minimal, local or non-invasive intervention indicated; limiting age-appropriate instrumental ADL, G3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL. G4: life-threatening consequences; urgent intervention indicated. G5: death related to AE. G3 and 4 abnormalities were reported in this outcome measure.
Time frame: From Day 1 of study treatment up to Week 52 of the treatment safety period
Follow-up Safety Period: Number of Participants With Chemistry Test Abnormalities
Chemistry Test Abnormalities included: hypernatremia, hyponatremia, hyperkalemia, hypokalemia, hypoglycemia, creatinine increased, blood lactate dehydrogenase increased, hypoalbuminemia, CPK increased, aspartate aminotransferase increased, alanine aminotransferase increased, blood bilirubin increased, alkaline phosphatase increased, chronic kidney disease, cholesterol high, hypertriglyceridemia. As per NCI CTCAE v5.0-G1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated, G2: moderate; minimal, local or non-invasive intervention indicated; limiting age-appropriate instrumental ADL, G3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL. G4: life-threatening consequences; urgent intervention indicated. Grade 5: death related to AE. G3 and 4 abnormalities were reported in this outcome measure.
Time frame: From Week 52 to Week 54 of the follow-up safety period
Change From Observation Period in the Number of Migraine Days by Pain Intensity at Every 4 Week Interval and Overall Period
The number of migraine days and severity of migraine attacks was analyzed for every 4-week interval and overall period during long-term treatment with rimegepant in participants was compared to the observation period. Pain intensity of migraine was graded into mild, moderate, or severe and severity was judged by investigator.
Time frame: Baseline (observation period); Week 1 to 4, 5 to 8, 9 to 12, 13 to 16, 17 to 20, 21 to 24, 25 to 28, 29 to 32, 33 to 36, 37 to 40, 41 to 44, 45 to 48, 49 to 52 and Overall (Week 1 to 52)
A total of 241 participants were enrolled in the study. 240 participants received study treatment.
| Milestone | Rimegepant 75 Milligrams (mg) Orally Disintegrating Tablets (ODT) |
|---|---|
| Started | 241 |
| Treated | 240 |
| Completed | 208 |
| Not completed | 33 |
| Withdrew: Non-compliance with study schedule | 9 |
| Withdrew: Withdrawal by subject | 12 |
| Withdrew: Adverse event | 1 |
| Withdrew: Other | 11 |
An adverse event was any untoward medical occurrence in a clinical trial participant administered an investigational product that may present with symptoms/signs, disease, or laboratory abnormalities and which did not necessarily have a causal relationship with the investigational product. TEAEs were events that started after the first dose of trial drug and did not occur or worsen relative to the first dose.
| Participants | Rimegepant 75 mg ODT |
|---|---|
| Treatment Safety Period: Number of Participants With Treatment Emergent Adverse Events (TEAEs) | 203 |
An adverse event was any untoward medical occurrence in a clinical trial participant administered an investigational product that may present with symptoms/signs, disease, or laboratory abnormalities and which did not necessarily have a causal relationship with the investigational product. TEAEs were events that started after the first dose of trial drug and did not occur or worsen relative to the first dose.
| Participants | Rimegepant 75 mg ODT |
|---|---|
| Follow-up Safety Period: Number of Participants With TEAEs | 24 |
An adverse event was any untoward medical occurrence in a clinical trial participant administered an investigational product that may present with symptoms/signs, disease, or laboratory abnormalities and which did not necessarily have a causal relationship with the investigational product. SAE referred to any untoward medical occurrence that met any of the following criteria at any dose for a participant that received the investigational product: death, life-threatening, permanent or severe disability or incapacity, hospitalization or prolongation of hospitalization required or congenital anomaly or birth defect.
| Participants | Rimegepant 75 mg ODT |
|---|---|
| Treatment Safety Period: Number of Participants With Serious Adverse Events (SAEs) | 7 |
An adverse event was any untoward medical occurrence in a clinical trial participant administered an investigational product that may present with symptoms/signs, disease, or laboratory abnormalities and which did not necessarily have a causal relationship with the investigational product. SAE referred to any untoward medical occurrence that met any of the following criteria at any dose for a participant that received the investigational product: death, life-threatening, permanent or severe disability or incapacity, hospitalization or prolongation of hospitalization required or congenital anomaly or birth defect.
| Participants | Rimegepant 75 mg ODT |
|---|---|
| Follow-up Safety Period: Number of Participants With SAEs | 0 |
An AE was any untoward medical occurrence in a clinical trial participant administered an investigational product that may present with symptoms/signs, disease, or laboratory abnormalities and which did not necessarily had a causal relationship with the investigational product. AEs that led to study drug discontinuation were reported in this outcome measure.
| Participants | Rimegepant 75 mg ODT |
|---|---|
| Treatment Safety Period: Number of Participants With AEs Leading to Study Drug Discontinuation | 1 |
An AE was any untoward medical occurrence in a clinical trial participant administered an investigational product that may present with symptoms/signs, disease, or laboratory abnormalities and which did not necessarily had a causal relationship with the investigational product. AEs that led to study drug discontinuation were reported in this outcome measure.
| Participants | Rimegepant 75 mg ODT |
|---|---|
| Follow-up Safety Period: Number of Participants With AEs Leading to Study Drug Discontinuation | 0 |
ECG abnormalities criteria included: QT Interval Corrected Using Fridericia's Formula (QTcF) millisecond (msec): less than or equal to (\<=)450, 450 - \<=480, 480- \<=500, greater than (\>)500.
| Participants | Rimegepant 75 mg ODT |
|---|---|
| <=450 | 225 |
| 450 - <= 480 | 6 |
| 480 - <= 500 | 0 |
| > 500 | 0 |
ECG abnormalities criteria included: QTcF msec: \<=450, 450 - \<=480, 480- \<=500, \>500.
| Participants | Rimegepant 75 mg ODT |
|---|---|
| <=450 | 209 |
| 450 - <= 480 | 2 |
| 480 - <= 500 | 0 |
| >500 | 2 |
Vital signs abnormalities included blood pressure (BP) millimeters of mercury (mmHg): systolic BP \<90 and \>140; diastolic BP \<50 and \>90 and pulse rate (beats per minute) :\<40 and \>120.
| Participants | Rimegepant 75 mg ODT |
|---|---|
| Systolic BP <90 | 12 |
| Systolic BP >140 | 9 |
| Diastolic BP <50 | 1 |
| Diastolic BP >90 | 17 |
| Pulse rate <40 | 0 |
| Pulse rate >120 | 0 |
Vital signs abnormalities included BP mmHg: systolic BP \<90 and \>140; diastolic BP \<50 and \>90 and pulse rate (beats per minute) :\<40 and \>120.
| Participants | Rimegepant 75 mg ODT |
|---|---|
| Systolic BP <90 | 1 |
| Systolic BP >140 | 1 |
| Diastolic BP <50 | 0 |
| Diastolic BP >90 | 5 |
| Pulse rate <40 | 0 |
| Pulse rate >120 | 0 |
Hematology parameters included: hemoglobin increased, anemia, leukocytosis, white blood cell decreased, platelet count decreased, neutrophil count decreased, lymphocyte count increased, lymphocyte count decreased. As per National Cancer Institute of Common Terminology Criteria for Adverse Events (NCI CTCAE) version(v)5.0-Grade(G) 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated, Grade 2: moderate; minimal, local or non-invasive intervention indicated; limiting age appropriate instrumental activities of daily living (ADL), Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL. Grade 4: life-threatening consequences; urgent intervention indicated. Grade 5: death related to AE. Grade 3 and 4 abnormalities were reported in this outcome measure.
| Participants | Rimegepant 75 mg ODT |
|---|---|
| Hemoglobin increased | 0 |
| Anemia | 1 |
| Leukocytosis | 0 |
| White blood cell decreased | 1 |
| Platelet count decreased | 0 |
| Neutrophil count decreased | 1 |
| Lymphocyte count increased | 0 |
| Lymphocyte count decreased | 1 |
Hematology parameters included: hemoglobin increased, anemia, leukocytosis, white blood cell decreased, platelet count decreased, neutrophil count decreased, lymphocyte count increased, lymphocyte count decreased. As per NCI CTCAE v5.0-Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated, Grade 2: moderate; minimal, local or non-invasive intervention indicated; limiting age-appropriate instrumental ADL, Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL. Grade 4: life-threatening consequences; urgent intervention indicated. Grade 5: death related to AE. Grade 3 and 4 abnormalities were reported in this outcome measure.
| Participants | Rimegepant 75 mg ODT |
|---|---|
| Hemoglobin increased | 0 |
| Anemia | 0 |
| Leukocytosis | 0 |
| White blood cell decreased | 0 |
| Platelet count decreased | 0 |
| Neutrophil count decreased | 1 |
| Lymphocyte count increased | 0 |
| Lymphocyte count decreased | 0 |
Chemistry Test Abnormalities included: hypernatremia, hyponatremia, hyperkalemia, hypokalemia, hypoglycemia, creatinine increased, blood lactate dehydrogenase increased, hypoalbuminemia, creatine phosphokinase (CPK) increased, aspartate aminotransferase increased, alanine aminotransferase increased, blood bilirubin increased, alkaline phosphatase increased, chronic kidney disease, cholesterol high, hypertriglyceridemia. As per NCI CTCAE v5.0-G1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated, G2: moderate; minimal, local or non-invasive intervention indicated; limiting age-appropriate instrumental ADL, G3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL. G4: life-threatening consequences; urgent intervention indicated. G5: death related to AE. G3 and 4 abnormalities were reported in this outcome measure.
| Participants | Rimegepant 75 mg ODT |
|---|---|
| Hypernatremia | 0 |
| Hyponatremia | 0 |
| Hyperkalemia | 0 |
| Hypokalemia | 1 |
| Hypoglycemia | 0 |
| Creatinine increased | 0 |
| Blood lactate dehydrogenase increased | 0 |
| Hypoalbuminemia | 0 |
| CPK increased | 4 |
| Aspartate aminotransferase increased | 1 |
| Alanine aminotransferase increased | 0 |
| Blood bilirubin increased | 0 |
| Alkaline phosphatase increased | 0 |
| Chronic kidney disease | 0 |
| Cholesterol high | 0 |
| Hypertriglyceridemia | 2 |
Chemistry Test Abnormalities included: hypernatremia, hyponatremia, hyperkalemia, hypokalemia, hypoglycemia, creatinine increased, blood lactate dehydrogenase increased, hypoalbuminemia, CPK increased, aspartate aminotransferase increased, alanine aminotransferase increased, blood bilirubin increased, alkaline phosphatase increased, chronic kidney disease, cholesterol high, hypertriglyceridemia. As per NCI CTCAE v5.0-G1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated, G2: moderate; minimal, local or non-invasive intervention indicated; limiting age-appropriate instrumental ADL, G3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL. G4: life-threatening consequences; urgent intervention indicated. Grade 5: death related to AE. G3 and 4 abnormalities were reported in this outcome measure.
| Participants | Rimegepant 75 mg ODT |
|---|---|
| Hypernatremia | 0 |
| Hyponatremia | 0 |
| Hyperkalemia | 0 |
| Hypokalemia | 1 |
| Hypoglycemia | 0 |
| Creatinine increased | 0 |
| Blood lactate dehydrogenase increased | 0 |
| Hypoalbuminemia | 0 |
| CPK increased | 0 |
| Aspartate aminotransferase increased | 0 |
| Alanine aminotransferase increased | 0 |
| Blood bilirubin increased | 0 |
| Alkaline phosphatase increased | 0 |
| Chronic kidney disease | 0 |
| Cholesterol high | 0 |
| Hypertriglyceridemia | 0 |
The number of migraine days and severity of migraine attacks was analyzed for every 4-week interval and overall period during long-term treatment with rimegepant in participants was compared to the observation period. Pain intensity of migraine was graded into mild, moderate, or severe and severity was judged by investigator.
| Days | Rimegepant 75 mg ODT |
|---|---|
| Week 1 to Week 4 | -1.7 ± 3.8 |
| Week 5 to Week 8 | -2.4 ± 4.5 |
| Week 9 to Week 12 | -3.4 ± 4.2 |
| Week 13 to Week 16 | -3.7 ± 4.6 |
| Week 17 to Week 20 | -4.4 ± 4.6 |
| Week 21 to Week 24 | -4.8 ± 4.6 |
| Week 25 to Week 28 | -5.2 ± 4.6 |
| Week 29 to Week 32 | -4.8 ± 4.7 |
| Week 33 to Week 36 | -5.2 ± 4.5 |
| Week 37 to Week 40 | -5.5 ± 5.1 |
| Week 41 to Week 44 | -5.7 ± 4.7 |
| Week 45 to Week 48 | -5.6 ± 4.7 |
| Week 49 to Week 52 | -5.6 ± 5.5 |
| Overall | -2.8 ± 4.1 |
Collected over From Day 1 of study treatment up to Week 54. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rimegepant 75 mg ODT | 1/240 (0.4%) | 7/240 (2.9%) | 201/240 (83.8%) |
| Event | Rimegepant 75 mg ODT |
|---|---|
| Arteriosclerosis coronary arteryCardiac disorders | 1/240 |
| PneumoniaInfections and infestations | 1/240 |
| Clavicle fractureInjury, poisoning and procedural complications | 1/240 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 1/240 |
| Benign breast neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/240 |
| Brain injuryNervous system disorders | 1/240 |
| Varicose veinVascular disorders | 1/240 |
| Event | Rimegepant 75 mg ODT |
|---|---|
| COVID-19Infections and infestations | 100/240 |
| Upper respiratory tract infectionInfections and infestations | 28/240 |
| HyperuricaemiaMetabolism and nutrition disorders | 18/240 |
| NasopharyngitisInfections and infestations | 17/240 |
| HyperlipidaemiaMetabolism and nutrition disorders | 16/240 |
| PyrexiaGeneral disorders | 13/240 |
| Weight increasedInvestigations | 11/240 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 10/240 |
| Hepatic function abnormalHepatobiliary disorders | 10/240 |
| Weight decreasedInvestigations | 9/240 |
Full Analysis set included all participants who were enrolled and received at least one dose of the investigational product.
| Age, Continuous(Years) | Rimegepant 75mg ODT |
|---|---|
| Mean | 39.1 ± 10.97 |
| Sex: Female, Male(Participants) | Rimegepant 75mg ODT |
|---|---|
| Female | 192 |
| Male | 48 |
| Race (NIH/OMB)(Participants) | Rimegepant 75mg ODT |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 240 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 0 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Race/Ethnicity, Customized(Participants) | Rimegepant 75mg ODT |
|---|---|
| Han | 231 |
| Unknown or not reported | 9 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from May 2022 to primary completion in Feb 2024, 20 months.
Results were first posted in Feb 2025, 1 year after primary completion.
Of 114 industry-sponsored phase 3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's 20 months is above that.
Counting every sponsor, half of 140 studies reached it within 19 months; a quarter within 12 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rimegepant